Dexcom Inc (NASDAQ: DXCM) open the trading on Thursday, with a bit cautious approach as it glided -0.50% to $139.62, before settling in for the price of $140.32 at the close. Taking a more long-term approach, DXCM posted a 52-week range of $74.75-$142.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 28.80% over the last 5 years. Nevertheless, stock’s Earnings Per Share (EPS) this year is 15.38%. This publicly-traded company’s shares outstanding now amounts to $385.40 million, simultaneously with a float of $377.37 million. The organization now has a market capitalization sitting at $53.82 billion. At the time of writing, stock’s 50-day Moving Average stood at $128.02, while the 200-day Moving Average is $114.79.
Dexcom Inc (DXCM) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Medical Devices industry. Dexcom Inc’s current insider ownership accounts for 2.11%, in contrast to 98.94% institutional ownership. According to the most recent insider trade that took place on Apr 08 ’24, this organization’s President CEO and Chairman sold 49,633 shares at the rate of 138.30, making the entire transaction reach 6,864,136 in total value, affecting insider ownership by 283,893. Preceding that transaction, on Mar 28 ’24, Company’s EVP Chief Legal Officer sold 2,624 for 140.04, making the whole transaction’s value amount to 367,472. This particular insider is now the holder of 68,682 in total.
Dexcom Inc (DXCM) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 12/30/2023 suggests? It has posted $0.5 earnings per share (EPS) beating the forecaster’s viewpoint (set at $0.43) by $0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.39 per share during the current fiscal year.
Dexcom Inc’s EPS increase for this current 12-month fiscal period is 15.38% and is forecasted to reach 2.23 in the upcoming year.
Dexcom Inc (NASDAQ: DXCM) Trading Performance Indicators
Let’s observe the current performance indicators for Dexcom Inc (DXCM). It’s Quick Ratio in the last reported quarter now stands at 2.48. The Stock has managed to achieve an average true range (ATR) of 4.05. Alongside those numbers, its PE Ratio stands at $106.52, and its Beta score is 1.21. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 14.86. Similarly, its price to free cash flow for trailing twelve months is now 105.15.
In the same vein, DXCM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 1.31, a figure that is expected to reach 0.27 in the next quarter, and analysts are predicting that it will be 2.23 at the market close of one year from today.
Technical Analysis of Dexcom Inc (DXCM)
[Dexcom Inc, DXCM] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 81.85% While, its Average True Range was 4.02.
Raw Stochastic average of Dexcom Inc (DXCM) in the period of the previous 100 days is set at 94.05%, which indicates a major rise in contrast to 77.63% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 32.77% that was lower than 33.73% volatility it exhibited in the past 100-days period.
